Pulmonary arterial hypertension nanotherapeutics: New pharmacological targets and drug delivery strategies

H Boucetta, L Zhang, A Sosnik, W He - Journal of Controlled Release, 2024 - Elsevier
Pulmonary arterial hypertension (PAH) is a rare, serious, and incurable disease
characterized by high lung pressure. PAH-approved drugs based on conventional pathways …

Nanomedicine-mediated therapeutic approaches for pulmonary arterial hypertension

E Mirhadi, P Kesharwani, TP Johnston… - Drug Discovery Today, 2023 - Elsevier
Highlights•Nanomedicine has emerged as a field with great opportunities to improve
treatment strategies.•Pulmonary arterial hypertension (PAH) is a serious and incurable …

Traditional Chinese medicine monomers: targeting pulmonary artery smooth muscle cells proliferation to treat pulmonary hypertension

X Yang, Y Yang, K Liu, C Zhang - Heliyon, 2023 - cell.com
Pulmonary hypertension (PH) is a complex multifactorial disease characterized by increased
pulmonary vascular resistance and pulmonary vascular remodeling (PVR), with high …

Green Production Pathways, Instability, and Stability of Resveratrol: A Systematic Review

X Jiang, L Zuo, S Gao, Q Yang, Y Li… - Journal of Food …, 2025 - Wiley Online Library
Resveratrol (RES) is a nonflavonoid polyphenolic compound present in various plant
species. Extensive research has confirmed the diverse biological activities of RES …

Nanomedicine-based treatment: An emerging therapeutical strategy for pulmonary hypertension

S Wang, Q Chen, T Zhao, K Ai, C Hu - Nano Research, 2023 - Springer
Pulmonary hypertension (PH) can cause breathing difficulty, a rapid decline of exercise
capacity, heart failure, and eventually death of the patients. The latest epidemiological study …